These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27494302)

  • 1. Drug repurposing: a new front in the war against Staphylococcus aureus.
    Das S; Dasgupta A; Chopra S
    Future Microbiol; 2016 Aug; 11():1091-9. PubMed ID: 27494302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants.
    Trombetta RP; Dunman PM; Schwarz EM; Kates SL; Awad HA
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30381352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing Ivacaftor for treatment of Staphylococcus aureus infections.
    Thakare R; Singh AK; Das S; Vasudevan N; Jachak GR; Reddy DS; Dasgupta A; Chopra S
    Int J Antimicrob Agents; 2017 Sep; 50(3):389-392. PubMed ID: 28694231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug repurposing for the treatment of staphylococcal infections.
    Thangamani S; Mohammad H; Younis W; Seleem MN
    Curr Pharm Des; 2015; 21(16):2089-100. PubMed ID: 25760334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing the Nonsteroidal Anti-inflammatory Drug Diflunisal as an Osteoprotective, Antivirulence Therapy for Staphylococcus aureus Osteomyelitis.
    Hendrix AS; Spoonmore TJ; Wilde AD; Putnam NE; Hammer ND; Snyder DJ; Guelcher SA; Skaar EP; Cassat JE
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5322-30. PubMed ID: 27324764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative approaches to treat
    Richter K; Van den Driessche F; Coenye T
    Essays Biochem; 2017 Feb; 61(1):61-70. PubMed ID: 28258230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prevalence of antiseptic resistance genes (qacA/B and smr) and antibiotic resistance in clinical Staphylococcus aureus strains].
    Nakipoğlu Y; Iğnak S; Gürler N; Gürler B
    Mikrobiyol Bul; 2012 Apr; 46(2):180-9. PubMed ID: 22639307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there any rationale for treatment of Staphylococcus aureus infections with antimicrobials that are determined to be ineffective in vitro?
    Uekötter A; Peters G; Becker K
    Clin Microbiol Infect; 2011 Aug; 17(8):1142-7. PubMed ID: 21672081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs for methicillin-resistant Staphylococcus aureus: an update.
    Kumar K; Chopra S
    J Antimicrob Chemother; 2013 Jul; 68(7):1465-70. PubMed ID: 23429643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial resistance: the example of Staphylococcus aureus.
    Lowy FD
    J Clin Invest; 2003 May; 111(9):1265-73. PubMed ID: 12727914
    [No Abstract]   [Full Text] [Related]  

  • 11. The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes.
    Cameron DR; Howden BP; Peleg AY
    Clin Infect Dis; 2011 Sep; 53(6):576-82. PubMed ID: 21865195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The redesign of oxazolidinone antibiotics in response to Staphylococcus aureus.
    Lupton D; Belousoff MJ
    Future Microbiol; 2017 Oct; 12():1113-1117. PubMed ID: 28876083
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prevalence of Staphylococcus aureus carriers of mecA gene susceptible to cefoxitine: OS-MRSA].
    Aleixandre-Górriz I; Domínguez-Márquez MV; Martínez-Macías O; Colomina J; Guerrero A
    Rev Esp Quimioter; 2014 Sep; 27(3):215-6. PubMed ID: 25229377
    [No Abstract]   [Full Text] [Related]  

  • 14. Australian Group on Antimicrobial Resistance Hospital-onset Staphylococcus aureus Surveillance Programme annual report, 2011.
    Coombs GW; Nimmo GR; Pearson JC; Collignon PJ; Bell JM; McLaws ML; Christiansen KJ; Turnidge JD;
    Commun Dis Intell Q Rep; 2013 Sep; 37(3):E210-8. PubMed ID: 24890956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Anti-staphylococcal and Anti-biofilm Compounds by Repurposing the Medicines for Malaria Venture Pathogen Box.
    Bhandari V; Chakraborty S; Brahma U; Sharma P
    Front Cell Infect Microbiol; 2018; 8():365. PubMed ID: 30406042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections.
    Thangamani S; Younis W; Seleem MN
    Sci Rep; 2015 Jun; 5():11596. PubMed ID: 26111644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The living croquet theory: The Staphylococcus aureus paradigm.
    Raoult D; Rolain JM
    Int J Antimicrob Agents; 2019 Jun; 53(6):724-725. PubMed ID: 30986524
    [No Abstract]   [Full Text] [Related]  

  • 18. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa.
    Shittu AO; Lin J
    BMC Infect Dis; 2006 Jul; 6():125. PubMed ID: 16875502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling the molecular basis of antimicrobial resistance in Staphylococcus aureus from the Democratic Republic of the Congo using whole genome sequencing.
    Phaku P; Lebughe M; Strauß L; Peters G; Herrmann M; Mumba D; Mellmann A; Muyembe-Tamfum JJ; Schaumburg F
    Clin Microbiol Infect; 2016 Jul; 22(7):644.e1-5. PubMed ID: 27102139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial resistance in clinical isolates of Staphylococcus aureus from hospital and community sources in southern Jamaica.
    Brown PD; Ngeno C
    Int J Infect Dis; 2007 May; 11(3):220-5. PubMed ID: 16815064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.